LXEO

Lexeo Therapeutics Inc

• Reuters·15h ago

  Lexeo CEO Richard Nolan Townsend disposes of 55,000 shares worth $313,137

• TipRanks·03/31 11:55

  Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

• TipRanks·03/31 11:20

  Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX)

• TipRanks·03/31 10:59

  Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

• TipRanks·03/30 23:52

  Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances

• Benzinga·03/30 20:30

  Lexeo Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate

• TipRanks·03/30 20:27

  Lexeo Therapeutics reports Q4 EPS (27c), consensus (30c)

• Seeking Alpha·03/30 20:12

  Lexeo Therapeutics GAAP EPS of -$0.27 beats by $0.04

• Reuters·03/30 20:10

  Lexeo publishes corporate deck highlighting cardiac gene therapies LX2006, LX2020 in rare diseases

• Dow Jones·03/30 20:06

  *Lexeo Therapeutics: Cash, Cash Equivalents and Investments of $246.6 M Expected to Provide Runway Into 2028 >LXEO

• Dow Jones·03/30 20:05

  *Lexeo Therapeutics 4Q Loss $20.9M >LXEO

• Dow Jones·03/30 20:05

  *Lexeo Therapeutics 4Q Loss/Shr 27c >LXEO

• Dow Jones·03/30 20:05

  Press Release: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

• TipRanks·03/08 20:55

  Controversial Prasad leaving FDA, NYT reports

• TipRanks·02/25 15:05

  Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)